Table 2 Outlines the impact of Mineralocorticoid Receptor Antagonists (MRA) on heart failure patients, specifically in terms of serum aldosterone and IL-6 levels
ADHF NYHA 3-4 | ADHF using MRA (e.g | P value | Compensated HF NYHA 2-3 | Compensated HF using MRA(e.g | P value | |
|---|---|---|---|---|---|---|
spironolactone 50- | spironolactone 25-50mg/d) | |||||
100mg/d) NYHA 3-4 | NYHA 2-3 | |||||
Serum | 157.44+/- | 273.95+/- | p=0.002 | 84.14+/- | 132.87+/-82.16 | P = 0.01 |
aldosterone | 89.78 | 175.69 | 38.26 | |||
Serum | 17.27+/- | 12.09+/-5.19 | 0.0174 | 6.12+/-0.91 | 4.53+/-0.49 | <0.0001 |
interleukin 6 | 10.36 |